---
layout: post
title: "Prospective Grant of an Exclusive Patent License: Development and Commercialization of Fusion Proteins for the Treatment of Growth Disorders and Diseases of Cartilage Degeneration"
date: 2026-02-05 18:58:26 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-05140
original_published: 2022-03-11 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: Development and Commercialization of Fusion Proteins for the Treatment of Growth Disorders and Diseases of Cartilage Degeneration

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** March 11, 2022 00:00 UTC
**Document Number:** 2022-05140

## Summary

The Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Cancer Institute, both institutes of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Cavalry Biosciences, Inc. of San Francisco, CA.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/03/11/2022-05140/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-fusion)
- API: https://www.federalregister.gov/api/v1/documents/2022-05140

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
